MTA3 and breast carcinoma: Besides, researchers found that expression of Six3 is negatively correlated with breast cancer malignancy and further studies on the mechanism revealed that Six3 recruits LSD1/NuRD(MTA3) complex to Wnt1 promoters, thus resulting in a reduction of Wnt1 expression levels in breast cancer [13].